This is all great to hear, imo.. a LH study, esp with 100, will fill up QUICKLY judging by the number of people trying to get screened by IncellDX’s panel.

“We use Leronlimab if we could get it”
Oh really?

Quote:

---

> Long-hauler protocol submission didn’t happen, debate about PE, modifying protocol, “hopefully” submit to FDA next week: 100 patients, 1:1 randomisation, fast enrolment, since no competition; holding off on Phase 3 moderate; all focus on CD-12


Read More: https://investorshangout.com/post/view?id=595...z6cy6v0F7K

---